208 related articles for article (PubMed ID: 16918588)
1. Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial.
Zinman B; Harris SB; Gerstein HC; Young TK; Raboud JM; Neuman J; Hanley AJ
Diabetes Obes Metab; 2006 Sep; 8(5):531-7. PubMed ID: 16918588
[TBL] [Abstract][Full Text] [Related]
2. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.
Zinman B; Harris SB; Neuman J; Gerstein HC; Retnakaran RR; Raboud J; Qi Y; Hanley AJ
Lancet; 2010 Jul; 376(9735):103-11. PubMed ID: 20605202
[TBL] [Abstract][Full Text] [Related]
3. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes.
Jones MR; Mudaliar S; Hernandez-Triana E; Unnikrishnan AG; Lai YL; Abby SL; Misir S; Jin X; Nagendran S
Curr Med Res Opin; 2009 Sep; 25(9):2239-49. PubMed ID: 19622007
[TBL] [Abstract][Full Text] [Related]
5. Reflecting on type 2 diabetes prevention: more questions than answers!
Rosenstock J
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():3-11. PubMed ID: 17877541
[TBL] [Abstract][Full Text] [Related]
6. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance.
Durbin RJ
Diabetes Obes Metab; 2004 Jul; 6(4):280-5. PubMed ID: 15171752
[TBL] [Abstract][Full Text] [Related]
7. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K
Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
[TBL] [Abstract][Full Text] [Related]
9. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.
Ponssen HH; Elte JW; Lehert P; Schouten JP; Bets D
Clin Ther; 2000 Jun; 22(6):709-18. PubMed ID: 10929918
[TBL] [Abstract][Full Text] [Related]
10. The prevention of type 2 diabetes: what is the evidence?
Chiasson JL; Brindisi MC; Rabasa-Lhoret R
Minerva Endocrinol; 2005 Sep; 30(3):179-91. PubMed ID: 16208307
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.
Caro JJ; Getsios D; Caro I; Klittich WS; O'Brien JA
Diabet Med; 2004 Nov; 21(11):1229-36. PubMed ID: 15498090
[TBL] [Abstract][Full Text] [Related]
12. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents.
Harden KA; Cowan PA; Velasquez-Mieyer P; Patton SB
J Am Acad Nurse Pract; 2007 Jul; 19(7):368-77. PubMed ID: 17680902
[TBL] [Abstract][Full Text] [Related]
13. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
14. Prevention of type 2 diabetes in the prediabetic population.
Maji D; Roy RU; Das S
J Indian Med Assoc; 2005 Nov; 103(11):609-11. PubMed ID: 16570766
[TBL] [Abstract][Full Text] [Related]
15. Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance.
Eriksson JG; Lehtovirta M; Ehrnström B; Salmela S; Groop L
J Intern Med; 2006 Jun; 259(6):553-60. PubMed ID: 16704555
[TBL] [Abstract][Full Text] [Related]
16. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
Flórez H
Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
[TBL] [Abstract][Full Text] [Related]
17. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Ratner RE; Christophi CA; Metzger BE; Dabelea D; Bennett PH; Pi-Sunyer X; Fowler S; Kahn SE;
J Clin Endocrinol Metab; 2008 Dec; 93(12):4774-9. PubMed ID: 18826999
[TBL] [Abstract][Full Text] [Related]
18. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.
Petersen JL; McGuire DK
Diab Vasc Dis Res; 2005 Feb; 2(1):9-15. PubMed ID: 16305067
[TBL] [Abstract][Full Text] [Related]
19. Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial.
Lian F; Li G; Chen X; Wang X; Piao C; Wang J; Hong Y; Ba Z; Wu S; Zhou X; Lang J; Liu Y; Zhang R; Hao J; Zhu Z; Li H; Fang Liu H; Cao A; Yan Z; An Y; Bai Y; Wang Q; Zhen Z; Yu C; Wang CZ; Yuan CS; Tong X
J Clin Endocrinol Metab; 2014 Feb; 99(2):648-55. PubMed ID: 24432995
[TBL] [Abstract][Full Text] [Related]
20. The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial.
Guardado-Mendoza R; Salazar-López SS; Álvarez-Canales M; Farfán-Vázquez D; Martínez-López YE; Jiménez-Ceja LM; Suárez-Pérez EL; Angulo-Romero F; Evia-Viscarra ML; Montes de Oca-Loyola ML; Durán-Pérez EG; Folli F; Aguilar-García A
Metabolism; 2020 Mar; 104():154054. PubMed ID: 31887309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
